{"disease":{"id":"leukemia-chronic","name":"leukemia chronic"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00626496","title":"Family Study of Lymphoproliferative Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07151820","title":"A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients","phase":"","overall_status":"COMPLETED","enrollment_count":2546,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT00898079","title":"Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":2545,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT07188428","title":"Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":2298,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05334069","title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT07374120","title":"Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting","phase":"","overall_status":"COMPLETED","enrollment_count":1480,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT01087333","title":"Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":1263,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05978141","title":"A Registry for People With T-cell Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT07091019","title":"A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT00471497","title":"A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":846,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01010061","title":"CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":787,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT01998880","title":"CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":787,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT02053610","title":"CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":787,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT07150793","title":"A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in Japan","phase":"","overall_status":"COMPLETED","enrollment_count":754,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05947851","title":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":735,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT02500407","title":"A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":713,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT03289182","title":"An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)","phase":"","overall_status":"COMPLETED","enrollment_count":701,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT01804686","title":"A Long-term Extension Study of PCI-32765 (Ibrutinib)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT01178086","title":"A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)","phase":"","overall_status":"COMPLETED","enrollment_count":681,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT01743989","title":"A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":620,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01886872","title":"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":547,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02130557","title":"A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":536,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT00171223","title":"An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":532,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04266301","title":"Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":530,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02115295","title":"Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":508,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03425591","title":"A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":508,"lead_sponsor_name":"Janssen-Cilag Ltd.","has_results":false},{"nct_id":"NCT02085798","title":"Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)","phase":"","overall_status":"COMPLETED","enrollment_count":503,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT04545333","title":"The clonoSEQ® Watch Registry","phase":"","overall_status":"TERMINATED","enrollment_count":465,"lead_sponsor_name":"Adaptive Biotechnologies","has_results":false},{"nct_id":"NCT03509896","title":"Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)","phase":"","overall_status":"COMPLETED","enrollment_count":463,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT03268954","title":"Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":454,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT02242942","title":"Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":445,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT02222272","title":"Effect of 2nd Gen TKI in CML","phase":"","overall_status":"COMPLETED","enrollment_count":432,"lead_sponsor_name":"European Society for Blood and Marrow Transplantation","has_results":false},{"nct_id":"NCT03959241","title":"TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":431,"lead_sponsor_name":"Medical College of Wisconsin","has_results":true},{"nct_id":"NCT03647215","title":"CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey","phase":"","overall_status":"COMPLETED","enrollment_count":427,"lead_sponsor_name":"Incyte Biosciences UK","has_results":false},{"nct_id":"NCT00602459","title":"Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":418,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02907359","title":"Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":417,"lead_sponsor_name":"Astex Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT07454850","title":"A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02164071","title":"Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies","phase":"","overall_status":"COMPLETED","enrollment_count":363,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT04877522","title":"Asciminib Roll-over Study","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":347,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04093570","title":"A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)","phase":"PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":332,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":false},{"nct_id":"NCT01488162","title":"An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia","phase":"","overall_status":"COMPLETED","enrollment_count":327,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04708054","title":"Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":324,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02910583","title":"Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":323,"lead_sponsor_name":"Pharmacyclics LLC.","has_results":true},{"nct_id":"NCT06130787","title":"Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy","phase":"NA","overall_status":"RECRUITING","enrollment_count":321,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false},{"nct_id":"NCT03331198","title":"Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":320,"lead_sponsor_name":"Juno Therapeutics, a Subsidiary of Celgene","has_results":false},{"nct_id":"NCT05963074","title":"A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":320,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT04256317","title":"A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":316,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":false},{"nct_id":"NCT06001385","title":"HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":313,"lead_sponsor_name":"Center for International Blood and Marrow Transplant Research","has_results":false},{"nct_id":"NCT03720561","title":"A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting","phase":"","overall_status":"COMPLETED","enrollment_count":312,"lead_sponsor_name":"Janssen-Cilag S.p.A.","has_results":false},{"nct_id":"NCT07290309","title":"Survivors Uniting for Remote Guided Exercise","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Colorado State University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}